HPV (Papilloma Human Virus) Vaccination in Young Women With Cystic Fibrosis and Followed in the Auvergne Rhône-Alpes Region
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 74
- 试验地点
- 3
- 主要终点
- Realization of human papillomavirus vaccination
研究概览
简要总结
The main risk factor for the development of cervical lesions is human papillomavirus (HPV) infection. Vaccination against human papillomavirus, which is offered to all girls aged 11 to 14, and catching up to girls aged 15 to 19, is an effective method of preventing cervical pathology. Despite this, human papillomavirus vaccination coverage remains low in France.
Some women with cystic fibrosis might need a transplantation, which is a factor associated with increased risk of human papillomavirus carriage and cervical pathology. An over-risk of cervical pathology would also be present in non-transplanted women with cystic fibrosis. Particular attention should therefore be paid to vaccination in this population.
The objective is to estimate the frequency of human papillomavirus vaccination in young patients with cystic fibrosis, and to evaluate the reasons for non-vaccination.
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Prospective
入排标准
- 年龄范围
- 11 Years 至 18 Years（Child, Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •girls with Cystic Fibrosis
- •followed in a pediatric or mixed Cystic Fibrosis center of the region Auvergne Rhône Alpes (AuRA)
- •aged 11 years or older
排除标准
- •Refusal to respond to the questionnaire
结局指标
主要结局
Realization of human papillomavirus vaccination
时间窗: 15 minutes
The main outcome is the prevalence of human papillomavirus vaccination in young women with Cystic fibrosis. This data is collected using a questionnaire : HPV vaccination performed : yes/no
次要结局
- Respect for the vaccinal plan(15 minutes)
- Type of vaccine used(15 minutes)
- Reasons for non-vaccination(15 minutes)